Maintenance of bronchodilator response for Advair Diskus 250/50 (fluticasone propionate/salmeterol) but not ipratropium/albuterol in patients with COPD

被引：2

作者：

Knobil, K ^{[1
]}

Kalberg, C ^{[1
]}

Merchant, K ^{[1
]}

Emmett, A ^{[1
]}

Cicale, M ^{[1
]}

机构：

[1] GlaxoSmithKline, Raleigh, NC USA

来源：

CHEST | 2004年 / 126卷 / 04期

关键词：

D O I：

10.1378/chest.126.4_MeetingAbstracts.807S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：807S / 807S

页数：1

共 50 条

[41] Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250μg vs fluticasone propionate 250μg in adults and adolescents with asthma IV:: Results
Palmqvist, M
Price, MJ
Sondhi, S
PHARMACOECONOMICS, 1999, 16 (Suppl 2) : 23 - 28
[42] Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/250μg vs Fluticasone Propionate 250μg in Adults and Adolescents with Asthma IV: Results
Mona Palmqvist
Martin J. Price
Seema Sondhi
PharmacoEconomics, 1999, 16 : 23 - 28
[43] Cost-effectiveness of fluticasone propionate/salmeterol (500/50 μg) in the treatment of COPD
Earnshaw, Stephanie R.
Wilson, Michele R.
Dalal, Anand A.
Chambers, Mike G.
Jhingran, Priti
Stanford, Richard
Mapel, Douglas W.
RESPIRATORY MEDICINE, 2009, 103 (01) : 12 - 21
[44] Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD
Tonnel, Andre-Bernard
Tillie-Leblond, Isabelle
Attali, Valerie
Bavelele, Zola
Lagrange, Olivier
RESPIRATORY MEDICINE, 2011, 105 (02) : 250 - 258
[45] Equivalent systemic exposure to fluticasone propionate/salmeterol following single inhaled doses of Advair Diskus® and Wixela™ Inhub™: Results of 3 pharmacokinetic equivalence studies
Ward, Jonathan K.
Wood, Nolan
Allan, Richard
Haughie, Scott
ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 360 - 360
[46] Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses of Advair® Diskus® and Wixela® Inhub® : Results of Three Pharmacokinetic Equivalence Studies
Ward, J. K.
Wood, N.
Allan, R.
Haughie, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[47] Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
Dalal, Anand A.
Shah, Manan
D'Souza, Anna O.
Chaudhari, Sham
Crater, Glenn
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 11 - 19
[48] Bronchodilator Response To Albuterol And Ipratropium Is Highly Predictive Of Subsequent Response To Short-Acting Bronchodilators In COPD
Pascoe, S.
Wu, W.
Zhu, C. -Q.
Singh, D.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
[49] Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD
Hoshino, Makoto
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[50] The effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on management of COPD patients
Mansori, Fariba
Khorasani, Anaiatolah Nemat
Boskabady, Mohammad Hossein
Boskabady, Morteza
CLINICAL RESPIRATORY JOURNAL, 2010, 4 (04): : 241 - 247

← 1 2 3 4 5 →